Trial record 1 of 1 for:
V940-001
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05933577 |
Recruitment Status :
Recruiting
First Posted : July 6, 2023
Last Update Posted : April 24, 2024
|
Sponsor:
Merck Sharp & Dohme LLC
Collaborator:
ModernaTX, Inc.
Information provided by (Responsible Party):
Merck Sharp & Dohme LLC
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | June 27, 2023 | ||||||
First Posted Date ICMJE | July 6, 2023 | ||||||
Last Update Posted Date | April 24, 2024 | ||||||
Actual Study Start Date ICMJE | July 19, 2023 | ||||||
Estimated Primary Completion Date | October 26, 2029 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
Recurrence-Free Survival (RFS) [ Time Frame: Up to approximately 74 months ] RFS is defined as the length of time from when the participant starts the study until either the cancer comes back, or the cancer spreads as assessed by the investigator, or death due to any cause.
|
||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||
Change History | |||||||
Current Secondary Outcome Measures ICMJE |
|
||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title ICMJE | A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) | ||||||
Official Title ICMJE | A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001) | ||||||
Brief Summary | The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning. | ||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 3 | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Masking Description: Double blind Primary Purpose: Treatment
|
||||||
Condition ICMJE | Melanoma | ||||||
Intervention ICMJE |
|
||||||
Study Arms ICMJE |
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Recruiting | ||||||
Estimated Enrollment ICMJE |
1089 | ||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||
Estimated Study Completion Date ICMJE | September 26, 2030 | ||||||
Estimated Primary Completion Date | October 26, 2029 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria: The main inclusion criteria include but are not limited to the following:
Exclusion Criteria: The main exclusion criteria include but are not limited to the following:
|
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE |
|
||||||
Listed Location Countries ICMJE | Argentina, Australia, Belgium, Brazil, Canada, Chile, Denmark, France, Germany, Greece, Israel, Italy, New Zealand, Poland, Portugal, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT05933577 | ||||||
Other Study ID Numbers ICMJE | V940-001 V940-001 ( Other Identifier: Merck ) 2023-503652-27-00 ( Other Identifier: EU CT number ) jRCT2041230169 ( Registry Identifier: jRCT ) |
||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement ICMJE |
|
||||||
Current Responsible Party | Merck Sharp & Dohme LLC | ||||||
Original Responsible Party | Same as current | ||||||
Current Study Sponsor ICMJE | Merck Sharp & Dohme LLC | ||||||
Original Study Sponsor ICMJE | Same as current | ||||||
Collaborators ICMJE | ModernaTX, Inc. | ||||||
Investigators ICMJE |
|
||||||
PRS Account | Merck Sharp & Dohme LLC | ||||||
Verification Date | April 2024 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |